A.G.E. Crosslink Breakers for Ocular Disorders

Project Details

Dr. Kaufman will determine whether the crosslink breaker compound, alagebrium, can alter intraocular pressure, improve the ease with which fluid passes out of the eye (outflow facility) via the conventional outflow pathways, and improve the ability to focus in response to a pharmacologic stimulus. Completion of these studies will clarify whether crosslink breaker compounds have any promise for further development as therapies for primary open angle glaucoma or presbyopia, the age-related loss of focal ability. This type of therapy would target a different pathway than all other glaucoma therapeutics and create the first pharmacologic therapy for presbyopia.